News
SOLA Biosciences Shares Preclinical Proof-of-Concept Data for SOL-257, a Gene Therapy Targeting Misfolded TDP-43 in ALS at 22nd Annual NEALS Meeting. October 03, 2023 04:46 PM Eastern Daylight Time.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback